kapsułki

DRUG5 trials

Sponsors

Medical University Of Lodz, OM Pharma SA, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy, Minoryx Therapeutics S.L., Opella Healthcare Group S.A.S.

Conditions

AdrenoleukodystrophyAlcoholic Liver DiseaseAttention-deficit hyperactivity disorderChronic Viral Hepatitis BMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MASHMetabolic Dysfunction-Associated SteatohepatitisMultiple sclerosisRecurrent wheezing

Phase 1

A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS

RecruitingCTIS2025-521508-23-00

Minoryx Therapeutics S.L.Adrenoleukodystrophy

Start: 2025-10-10Target: 73Updated: 2025-10-16

Phase 2

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo given in Children Aged 6 Months to 5 Years with Recurrent Wheezing

Active, not recruitingCTIS2024-511083-90-00

OM Pharma SARecurrent wheezing

Start: 2024-10-03Target: 85Updated: 2025-10-17

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.

Active, not recruitingCTIS2023-506862-30-00

Medical University Of LodzAttention-deficit hyperactivity disorder, Type 1 diabetes

Start: 2024-11-24Target: 150Updated: 2025-08-25

PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.

WithdrawnCTIS2025-520955-10-00

Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyMultiple sclerosis

Target: 210Updated: 2025-10-20

Phase 3

ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale® Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B

Not yet recruitingCTIS2025-521678-32-00

Opella Healthcare Group S.A.S.Alcoholic Liver Disease, Chronic Viral Hepatitis B, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MASH +1

Target: 466Updated: 2025-12-22